| Literature DB >> 30976187 |
Ezgi Öztaş1, Tugba Ekiz Yılmaz2, Elif Güzel2, Zehra Sezer2, Alper Okyar3, Gül Özhan1.
Abstract
OBJECTIVES: Type 2 diabetes (T2DM) is one of the most serious challenges of the 21th century with life-threatening complications and excessive health care costs. In diabetic patients, the main goal in T2DM treatment is the regulation of both blood glucose and lipid levels. For that, Gliclazide (GLZ), an oral antidiabetic, and Atorvastatin (ATV), a lipid lowering agent, are widely used drugs as combination. Diabetes has been reported severe impacts on male reproductive system; however, data obtained about ATV and GLZ treatment alone or in combination are conflicted or insufficient. Herein the effects of ATV and GLZ on male reproductive system in type 2 diabetic male rats have been investigated in the present study.Entities:
Keywords: Atorvastatin; Gliclazide; Immunohistochemistry; Male reproductive system; Streptozotocin induced type 2 diabetic rat; Ultrastructure
Year: 2019 PMID: 30976187 PMCID: PMC6438782 DOI: 10.1016/j.jsps.2019.01.003
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Blood glucose level, body and testis weights in all groups. STZ, diabetic rats; STZ + ATV, diabetic rats in Atorvastatin treatment; STZ + GLZ, diabetic rats in Gliclazide treatment; STZ + ATV/GLZ, diabetic rats in Atorvastatin/Gliclazide combination treatment.
| Parameter | Control | STZ | STZ + ATV | STZ + GLZ | STZ + ATV/GLZ | |
|---|---|---|---|---|---|---|
| Blood glucose (mg/dL) | ||||||
| Day 1 | 111.00 ± 3.42 | 222.92 ± 6.74 | 237.71 ± 11.51 | 226.85 ± 13.98 | 255.23 ± 15.15 | |
| Day 14 | 118.40 ± 3.50 | 200.85 ± 10.04 | 249.71 ± 10.77 | 170.35 ± 9.84 | 224.38 ± 18.34 | |
| Day 28 | 114.00 ± 2.39 | 195.42 ± 12.84 | 240.85 ± 15.03 | 137.30 ± 6.10 | 189.46 ± 14.89 | |
| Initial body weight (g) | 278.00 ± 6.04 | 267.20 ± 3.55 | 257.50 ± 2.80 | 268.30 ± 4.54 | 265.50 ± 5.62 | |
| Final body weight (g) | 303.20 ± 7.72 | 296.90 ± 6.75 | 275.50 ± 6.43 | 287.00 ± 9.04 | 279.20 ± 10.22 | |
| Testis weight (g) | 1.54 ± 0.03 | 1.52 ± 0.01 | 1.41 ± 0.03*† | 1.51 ± 0.02 | 1.45 ± 0.03 | |
| Somatic index | 0.56 ± 0.02 | 0.57 ± 0.01 | 0.55 ± 0.01 | 0.56 ± 0.02 | 0.55 ± 0.01 | |
Data were expressed as mean ± SEM.
p < 0.05 compared to control group.
p < 0.05 compared to STZ group.
Hormone levels in all groups. T, testosterone; E2, oestrogen; PROG, progesterone; LH, luteinizing hormone; FSH, follicle stimulating hormone; GnRH, gonadotropin releasing hormone; INHB, inhibin B. STZ, diabetic rats; STZ + ATV, diabetic rats in Atorvastatin treatment; STZ + GLZ, diabetic rats in Gliclazide treatment; STZ + ATV/GLZ, diabetic rats in Atorvastatin/Gliclazide combination treatment.
| Hormone | Control | STZ | STZ + ATV | STZ + GLZ | STZ + ATV/GLZ |
|---|---|---|---|---|---|
| T (nmol/L) | 11.27 ± 0.18 | 11.95 ± 0.28 | 10.89 ± 0.24 | 11.08 ± 0.51 | 10.39 ± 0.37 |
| E2 (ng/L) | 86.12 ± 1.207 | 87.62 ± 1.446 | 87.03 ± 1.672 | 82.38 ± 2.780 | 83.23 ± 1.228 |
| PROG (ng/mL) | 47.28 ± 1.645 | 53.66 ± 2.094 | 50.93 ± 1.502 | 50.70 ± 0.839 | 50.82 ± 1.046 |
| LH (mIU/mL) | 4.41 ± 0.114 | 4.50 ± 0.114 | 4.68 ± 0.171 | 4.15 ± 0.148 | 4.55 ± 0.103 |
| FSH (mIU/mL) | 5.80 ± 0.280 | 6.21 ± 0.223 | 5.95 ± 0.243 | 5.66 ± 0.217 | 6.10 ± 0.145 |
| GnRH (pg/mL) | 147.16 ± 5.382 | 160.20 ± 5.293 | 150.69 ± 6.402 | 149.81 ± 4.202 | 152.49 ± 5.143 |
| INHB (ng/L) | 197.81 ± 7.485 | 206.08 ± 10.445 | 198.70 ± 9.963 | 182.70 ± 5.973 | 218.01 ± 25.379 |
Data were expressed as mean ± SEM.
p < 0.05 compared to diabetic group.
Sperm count and morphological characteristics in all groups. STZ, diabetic rats; STZ + ATV, diabetic rats in Atorvastatin treatment; STZ + GLZ, diabetic rats in Gliclazide treatment; STZ + ATV/GLZ, diabetic rats in Atorvastatin/Gliclazide combination treatment.
| Control | STZ | STZ + ATV | STZ + GLZ | STZ + ATV/GLZ | ||
|---|---|---|---|---|---|---|
| Sperm count (millions/mL) | 543.60 ± 34.60 | 400.36 ± 32.01 | 350.80 ± 16.87 | 463.50 ± 39.69 | 377.86 ± 11.84 | |
| Sperm morphology (mean) | ||||||
| Normal | 194.6 | 172.8 | 185.9 | 185.8 | 179.4 | |
| Detached tail | 0.8 | 3.3 | 1.7 | 1.6 | 1.7 | |
| Detached head | 1.4 | 8.2 | 2.8 | 5.3 | 4.0 | |
| Flattened head | 0.2 | 0.6 | 0.1 | 0.2 | 0.6 | |
| Pin head | – | 0.1 | 0.1 | 0.3 | 0.4 | |
| Bent neck | 2.0 | 3.4 | 3.0 | 2.0 | 3.4 | |
| Bent tail | 0.8 | 5.1 | 4.0 | 3.1 | 6.1 | |
| Coiled tail | 0.2 | 6.5 | 2.4 | 1.7 | 4.4 | |
| Total abnormal sperm count | 5.4 | 27.2 | 14.1 | 14.2 | 20.6 | |
| Abnormal sperm (%) | 2.7 | 13.6 | 7.05 | 7.1 | 10.3 | |
Data were expressed as mean ± SEM.
p < 0.05 compared to control group.
p < 0.05 compared to STZ group.
Fig. 1Diameter of seminiferous tubules and thickness of epithelium in all groups. STZ, diabetic rats; STZ + ATV, diabetic rats in Atorvastatin treatment; STZ + GLZ, diabetic rats in Gliclazide treatment; STZ + ATV/GLZ, diabetic rats in Atorvastatin/Gliclazide combination treatment.
Fig. 2Normal morphology of seminiferous tubules, interstitial area and cellular attachments (A), claudin11 (→, F) and occludin (→, K) expression. Irregular and atrophied (*, B) seminiferous tubules, immature germ cells in lumen (►, B), abnormal cellular attachments (insert, B) and loss of cellular tight junctions (G, L) in diabetic rats. Disorganised germinal epithelium, cytoplasmic vacuoles (v, C), immature germ cells in lumen (insert, C), slightly increased claudin11 (H) and occludin (M) expression in ATV treated diabetic rats. Round seminiferous tubules with minimal loss of cellular attachments and normal interstitial area (D), well organized tight junctions (I, N) comparable to control group in GLZ treated diabetic rats. Immature germ cells in lumen (►, F), amorphous material in interstitial area (*, F), depleted interstitial area (ϯ, insert, F), increased expression of claudin11 (J) and occluding (O) in ATV/GLZ combination group. Staining: H&E (first column); Immunohistochemistry: Claudin11 (second column) and occludin (third column); Scale bars: 50 µm. STZ, diabetic rats; STZ + ATV, diabetic rats in Atorvastatin treatment; STZ + GLZ, diabetic rats in Gliclazide treatment; STZ + ATV/GLZ, diabetic rats in Atorvastatin/Gliclazide combination treatment.
Fig. 3Regular ultrastructure of Sertoli cell nuclei (►, A), spermatogenic cell (*, A), typical nucleus (*, B) and head of sperm (►, B) of a spermatid, nucleus (ϯ, C) and nucleolus (*, C) of a Sertoli cell, and a smooth endoplasmic reticulum (►, C) in control. Lipid droplets (L, D), irregular basal membrane (►, D), abnormal cellular attachments and separations (ϯ, E), abnormal cells and cellular debris (d, F) in the lumen (+, F) in diabetic rats. Vacuoles (v, G), irregular and thickened basal membrane (►, G), late spermatids (→, H) and immature spermatid (►, I) in the lumen (+, I) in STZ + ATV group. Minimal loss between spermatogenic cells (ϯ, J), normal mitochondria (→, K) and acrosomal cap of a spermatid (►, L) in STZ + GLZ group. Irregular basal membrane (►, M), a lipid droplet (L, M), swollen mitochondria without crista (→, N), vacuoles (v, O), and abnormal and normal sperm tails (►, O) in the lumen (+, O) in STZ + ATV/GLZ group. STZ, diabetic rats; STZ + ATV, diabetic rats in Atorvastatin treatment; STZ + GLZ, diabetic rats in Gliclazide treatment; STZ + ATV/GLZ, diabetic rats in Atorvastatin/Gliclazide combination treatment.